ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
ALX Oncology Holdings Inc. reported positive financial results for Q4 2023 and full year 2023, with a focus on evorpacept's success in the ASPEN-06 Phase 2 clinical trial. The company highlighted key findings, including a 52% overall response rate in the evorpacept combination treatment arm. ALX Oncology also executed a successful public offering generating $63.2 million in gross proceeds. The company anticipates significant clinical milestones in 2024 across various cancer types. Financially, the company ended 2023 with $218.1 million in cash, sufficient to fund operations into early 2026.
Positive
Positive results in the ASPEN-06 Phase 2 clinical trial for evorpacept in advanced HER2-positive gastric/GEJ cancer.
Successful execution of a public offering generating $63.2 million in gross proceeds.
Anticipation of significant clinical milestones in 2024 across different cancer types.
Strong financial position with $218.1 million in cash, cash equivalents, and investments as of December 31, 2023.
Negative
Increase in R&D expenses for the three months and year ended December 31, 2023 compared to the prior-year periods.
GAAP net loss of $45.5 million for Q4 2023 and $160.8 million for the year ended December 31, 2023.
Non-GAAP net loss of $38.7 million for Q4 2023 and $134.3 million for the year ended December 31, 2023.
The reported financial results from ALX Oncology Holdings Inc. indicate a significant increase in R&D expenses, which rose from $98.4 million in the prior year to $141.8 million. This uptick reflects the company's aggressive investment in expanding clinical trials and manufacturing of clinical trial materials for its lead product candidate, evorpacept. Notably, the company's cash position of $218.1 million, bolstered by a successful public offering that generated approximately $63.2 million, suggests a robust cash runway into early 2026. This financial cushion may reassure investors about the company's ability to sustain operations and continue its research without the immediate need for additional capital.
However, the widening GAAP net loss from $123.5 million to $160.8 million year-over-year raises concerns about the company's profitability trajectory. As ALX Oncology is still in the clinical stage of development, such losses are not uncommon, but they do emphasize the importance of the company's pipeline success. The positive interim results from the ASPEN-06 Phase 2 trial could be a pivotal factor in the company's future, potentially leading to increased investor confidence if the full data continues to demonstrate significant efficacy and safety.
The interim analysis of the ASPEN-06 Phase 2 clinical trial in advanced HER2-positive gastric/GEJ cancer reveals a notable overall response rate of 52 percent for the evorpacept combination treatment arm, which is a substantial improvement over the 22 percent for the control group. This finding is particularly compelling when compared to the benchmark ORR of 28 percent and mDOR of 4.4 months from the RAINBOW study, underscoring evorpacept's potential as a significant advancement in the treatment of this cancer type.
The safety profile consistency with prior trials adds to the compound's credibility, an essential consideration for both clinicians and investors. The anticipation of multiple data readouts over the next 12-18 months across various cancer types positions the company at the forefront of the CD47 immune checkpoint pathway, a promising target in immuno-oncology. The success of evorpacept could have profound implications for patients with limited treatment options and could significantly alter the competitive landscape in oncology therapeutics.
The strategic execution of an oversubscribed public offering following positive clinical trial results is indicative of ALX Oncology's market acumen. By capitalizing on the positive news, the company has effectively extended its financial runway, which may reduce the risk profile for current and potential investors. The timing of this offering, in conjunction with the detailed timeline for forthcoming clinical milestones, suggests a well-orchestrated effort to maintain investor interest and market momentum.
Market response to the interim analysis and subsequent financing activities will likely be contingent on the continued success of evorpacept in ongoing and future trials. The initiation of a Phase 3 registrational trial, a critical step towards potential commercialization, could serve as a significant catalyst for the company's valuation and stock performance. The market will closely monitor the upcoming data presentations at the AACR Annual Meeting and subsequent trial results to gauge the commercial viability of evorpacept and its potential impact on ALX Oncology's market position.
03/07/2024 - 04:03 PM
SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.
“This past year proved to be a profound growth period for ALX Oncology highlighted by evorpacept’s positive results in the prespecified randomized interim analysis of the ASPEN-06 Phase 2 clinical trial in advanced HER2-positive gastric/GEJ cancer,” said Jason Lettmann, Chief Executive Officer (“CEO”) of ALX Oncology. “Notably, this outcome is particularly important as it represents the first promising activity in a randomized trial in solid tumors in the CD47 space and further underscores evorpacept’s differentiation. Over the next 12-18 months, we expect to report multiple value inflection datapoints, with the goal of advancing evorpacept’s potential beyond anti-cancer antibodies through ongoing combination studies with ADCs and checkpoint inhibitors. With nine ongoing trials, our goal is to expand evorpacept’s value to other tumor types including breast, NHL, multiple myeloma and urothelial cancers as well as accelerate our efforts to identify new indications around this highly differentiated asset.”
Fourth Quarter 2023 Highlights
Appointed long-standing board member, Jason Lettmann to CEO, while co-founder and previous CEO, Jaume Pons, Ph.D., transitioned to Chief Scientific Officer in September. Reported positive results from a prespecified interim analysis of the Phase 2 randomized multi-center international clinical trial of ASPEN-06 for the treatment of advanced HER2-positive gastric/gastroesophageal junction (“GEJ”) cancer in October. Key findings from the 54 randomized subjects, which included those previously treated with ENHERTU® (fam-trastuzumab deruxtecan-nxki) and/or immune checkpoint inhibitors, reported a confirmed overall response rate (“ORR”) of 52 percent in the evorpacept combination treatment arm compared to 22 percent for the control group of trastuzumab + CYRAMZA® (ramucirumab) + paclitaxel (“TRP”). Median duration of response (“mDOR”) was not reached for the evorpacept TRP combination treatment arm compared to 7.4 months for the control group of TRP. The safety profile of evorpacept was consistent with the Company’s previous clinical trials and remained well-tolerated in this reported treatment combination. The interim results compared favorably to the efficacy results reported for CYRAMZA + paclitaxel in the RAINBOW study (ORR of 28 percent and mDOR of 4.4 months), which currently serves as the regulatory benchmark and global standard-of-care for second-line gastric/GEJ cancer. Executed an oversubscribed underwritten public offering that generated gross proceeds of approximately $63.2 million during October, which helps to extend the Company’s expected cash runway into early 2026. The follow-on offering closely followed the report of the positive interim analysis of the Phase 2 ASPEN-06 clinical trial in advanced HER2-positive gastric/GEJ cancer. ALX Oncology sold 8,663,793 shares of common stock, which included 1,293,103 shares of common stock pursuant to the full exercise of the underwriters’ option to purchase additional shares and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,250,000 shares of common stock in the offering. The shares of common stock were sold at a public offering price of $6.38 per share (the closing price on October 4, 2023), and the pre-funded warrants were sold at a public offering price of $6.37 9 per pre-funded warrant. Anticipated 2024 Clinical Milestones for Evorpacept’s Maturing Pipeline Development
Non-Hodgkin Lymphoma – Data from a Phase 1b IST with rituximab + lenalidomide will be presented in an oral presentation in a Clinical Trials Minisymposium session at the AACR Annual Meeting 2024 on Tuesday, April 9, 2024, from 2:30 pm – 4:30 pm PT. Urothelial Carcinoma – Data from a Phase 1b ASPEN-07 clinical trial with PADCEV® (enfortumab vedotin-ejfv) (Q2 2024) Gastric/GEJ Cancer – Top line results from all 122 subjects in a Phase 2 randomized clinical trial of ASPEN-06 (June-July 2024) Breast Cancer – Top line results from a Phase 1b I-SPY TRIAL with ENHERTU (Q4 2024) Head and Neck Squamous Cell Carcinoma – Top line results from a Phase 2 randomized clinical trial of ASPEN-03 with KEYTRUDA® (pembrolizumab) (Q4 2024/Q1 2025) Head and Neck Squamous Cell Carcinoma – Top line results from a Phase 2 randomized clinical trial of ASPEN-04 with KEYTRUDA and chemotherapy (Q4 2024/Q1 2025) Gastric/GEJ Cancer – Initiation of Phase 3 registrational randomized clinical trial for evorpacept (Q4 2024) 2023 Full Year and Fourth Quarter Financial Results:
Cash, Cash Equivalents and Investments: Cash, cash equivalents and investments as of December 31, 2023, were $218.1 million . The Company believes its cash, cash equivalents, and investments along with the ability to draw down an additional $40 million of its term loan are sufficient to fund planned operations into early 2026.Research and Development (“R&D”) Expenses: R&D expenses consist primarily of pre-clinical, clinical and manufacturing expenses related to the development of the Company’s current lead product candidate, evorpacept, and R&D employee-related expenses. These expenses for the three months ended December 31, 2023, were $41.8 million , compared to $25.2 million for the prior-year period. The increase was primarily attributable to an increase of $13.6 million in clinical costs from an increase in the number of active trials and patient enrollment as well as manufacturing of clinical trial materials to support a higher number of active clinical trials and future expected patient enrollment related to the advancement of evorpacept. R&D expenses for the year ended December 31, 2023 were $141.8 million , compared to $98.4 million for the prior-year period.General and Administrative (“G&A”) Expenses: G&A expenses consist primarily of administrative employee-related expenses, legal and other professional fees, patent filing and maintenance fees, and insurance. These expenses for the three months ended December 31, 2023, were $6.2 million , compared to $7.0 million for the prior year period. G&A expenses for the year ended December 31, 2023 were $28.5 million , compared to $29.0 million for the prior-year period.Net loss: GAAP net loss was $45.5 million for the fourth quarter ended December 31, 2023, or ($0.93) per basic and diluted share, as compared to a GAAP net loss of $30.7 million for the fourth quarter ended December 31, 2022, or ($0.75) per basic and diluted share. GAAP net loss was $160.8 million for the year ended December 31, 2023, or ($3.74) per basic and diluted share, as compared to a GAAP net loss of $123.5 million for the year ended December 31, 2022, or ($3.03) per basic and diluted share. Non-GAAP net loss was $38.7 million for the fourth quarter ended December 31, 2023, as compared to a non-GAAP net loss of $24.4 million for the fourth quarter ended December 31, 2022. Non-GAAP net loss was $134.3 million for the year ended December 31, 2023, as compared to a non-GAAP net loss of $99.6 million for the year ended December 31, 2022. A reconciliation of GAAP to non-GAAP financial results can be found at the end of this news release.About ALX Oncology
ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 immune checkpoint inhibitor and bridge the innate and adaptive immune system. ALX Oncology’s lead product candidate, evorpacept, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. To date, evorpacept has been dosed in over 500 subjects and has demonstrated promising activity and a favorable tolerability profile across a range of hematologic and solid malignancies in combination with various leading anti-cancer antibodies. ALX Oncology is currently focusing on combining evorpacept with anti-cancer antibodies, ADCs, and PD-1/PD-L1 immune checkpoint inhibitors.
Evorpacept’s Unique Profile: Anchored by a Rational Design and Dual Development Pillars
Rationally engineered with an inactive Fc effector function, evorpacept’s clinical data to date has demonstrated a substantially improved safety profile over other anti-CD47 molecules in the clinic with an active Fc (i.e., binding the Fc gamma receptor on macrophages). This best-in-class safety profile allows for higher dosage with minimal overlapping toxicity in the combination treatment setting. CD47 expressed on cancer cells binds to its receptor SIRP alpha, which is predominantly expressed on two cell types: macrophages and dendritic cells. The Company’s pipeline of therapeutic candidates with standard-of-care agents include:
Anti-cancer antibodies (the “ don’t eat me ” signal): evorpacept enables Fc-mediated antibody-dependent phagocytosis by macrophages in combination with anti-cancer antibodies (e.g., Herceptin® ) with an active Fc domain, which is otherwise impaired by CD47 expression on cancer cells binding to SIRP alpha on macrophages. This same mechanism of action applies to ADCs.PD-1/PD-L1 immune checkpoint inhibitors (the “ don’t activate T-cells ” signal) : evorpacept enables T-cell activation by dendritic cells that are constitutively inhibited by CD47 expression on cancer cells binding to SIRP alpha on dendritic cells. Activated dendritic cells present neoantigens to T-cells that once activated will kill cancer cells when the PD-1/PD-L1 inhibitory interaction is blocked by T-cell checkpoint inhibitors.Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements regarding future results of operations and financial position, business strategy, product candidates, planned preclinical studies and clinical trials, results of clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, plans and objects of management for future operations, as well as statements regarding industry trends. Such forward-looking statements are based on ALX Oncology’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause ALX Oncology’s actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These and other risks are described more fully in ALX Oncology’s filings with the Securities and Exchange Commission (“SEC”), including ALX Oncology’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other documents ALX Oncology files with the SEC from time to time. Except to the extent required by law, ALX Oncology undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
ALX ONCOLOGY HOLDINGS INC. Consolidated Statements of Operations Three Months Ended Year Ended December 31, December 31, 2023 2022 2023 2022 Operating expenses: Research and development $ 41,784 $ 25,197 $ 141,795 $ 98,400 General and administrative 6,239 7,022 28,483 29,036 Total operating expenses 48,023 32,219 170,278 127,436 Loss from operations (48,023 ) (32,219 ) (170,278 ) (127,436 ) Interest income 2,995 1,807 10,649 4,278 Interest expense (415 ) (231 ) (1,565 ) (238 ) Other income (expense), net (29 ) (2 ) 389 (22 ) Loss before income taxes (45,472 ) (30,645 ) (160,805 ) (123,418 ) Income tax (provision) benefit — (64 ) — (64 ) Net loss $ (45,472 ) $ (30,709 ) $ (160,805 ) $ (123,482 ) Net loss per share, basic and diluted $ (0.93 ) $ (0.75 ) $ (3.74 ) $ (3.03 ) Weighted-average shares of common stock used to compute net loss per shares, basic and diluted 48,995,998 40,755,520 42,987,767 40,699,612
Consolidated Balance Sheet Data December 31, December 31, 2023 2022 Cash, cash equivalents and investments $ 218,147 $ 282,906 Total assets $ 242,553 $ 306,489 Total liabilities $ 52,841 $ 43,025 Accumulated deficit $ (486,272 ) $ (325,467 ) Total stockholders’ equity $ 189,712 $ 263,464
GAAP to Non-GAAP Reconciliation
Three Months Ended Year Ended December 31, December 31, 2023 2022 2023 2022 GAAP net loss, as reported $ (45,472 ) $ (30,709 ) $ (160,805 ) $ (123,482 ) Adjustments: Stock-based compensation expense 6,721 6,295 26,273 23,839 Accretion of term loan discount and issuance costs 64 44 250 44 Total adjustments 6,785 6,339 26,523 23,883 Non-GAAP net loss $ (38,687 ) $ (24,370 ) $ (134,282 ) $ (99,599 )
Use of Non-GAAP Financial Measures
We supplement our consolidated financial statements presented on a GAAP basis by providing additional measures which may be considered “non-GAAP” financial measures under applicable SEC rules. We believe that the disclosure of these non-GAAP financial measures provides our investors with additional information that reflects the amounts and financial basis upon which our management assesses and operates our business. These non-GAAP financial measures are not in accordance with generally accepted accounting principles and should not be viewed in isolation or as a substitute for reported, or GAAP, net loss, and are not a substitute for, or superior to, measures of financial performance performed in conformity with GAAP.
“Non-GAAP net loss” is not based on any standardized methodology prescribed by GAAP and represents GAAP net loss adjusted to exclude stock-based compensation expense and accretion of term loan discount and issuance costs. Non-GAAP financial measures used by ALX Oncology may be calculated differently from, and therefore may not be comparable to, non-GAAP measures used by other companies.
The trial reported a 52% overall response rate in the evorpacept combination treatment arm.
The public offering generated approximately $63.2 million in gross proceeds.
Anticipated milestones include data presentations, top line results, and initiation of Phase 3 trials across various cancer types.
The company had $218.1 million in cash, cash equivalents, and investments as of December 31, 2023.
The GAAP net loss was $45.5 million for the fourth quarter ended December 31, 2023.
R&D expenses increased for the three months and year ended December 31, 2023, compared to the prior-year periods.
The non-GAAP net loss was $38.7 million for the fourth quarter ended December 31, 2023.
